It also remains unknown whether the combination of BTK and BCL2 inhibitors is superior to BTK inhibitor monotherapy or BCL2 inhibitor plus a CD20-antibody in patients with CLL. Here, BTK is linked to B-cell chronic lymphocytic leukemia.